Astellas Pharma and Theravance File European MAA for Antibiotic Drug

Astellas Pharma, a Japanese pharmaceutical company, and Theravance, a US-based biopharmaceutical company, have reported that Astellas Pharma Europe submitted a marketing authorization application, or MAA, to the European Medicines Agency for telavancin.

According to Theravance, telavancin is a bactericidal, once-daily injectable lipoglycopeptide antibiotic, for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia, and complicated skin and soft tissue infections in adults.